34.47
+0.23%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pharvaris
Its shares trade under the ticker PHVS. It has been listed since 5 February 2021.
Pharvaris NV operates as a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2021-02-05. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 5 Feb 2021
- Employees
- 129
- Website
- pharvaris.com ↗
- Head office
- J.H. OORTWEG 21, LEIDEN
- Incorporated in
- P7
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Berndt ModigChief Executive Officer, Co-Founder, Executive Director€721,585
- Dr. Jochen KnolleCo-Founder, Chief Operating Officer, Chief Scientific Officer
- Mr. Hans SchikanCo-Founder, Non-Executive Director, since 2019€50,940
- Dr. Anne LesageCo-Founder, Chief Early Development Officer
- Mr. David NassifChief Financial Officer
- Ms. Anna NijdamHead of Finance, Principal Accounting Officer
- Dr. Morgan ConnChief Business Officer
- Dr. Peng LuChief Medical Officer
- Dr. Wim SouverijnsChief Community Engagement and Commercial Officer
- Dr. Elisabeth BjorkNon-Executive Director
- Dr. Anne De Jonge SchuermansNon-Executive Director
- Dr. Robert GlassmanNon-Executive Director€28,900
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pharvaris NV has 129 employees in the Health Care sector with a focus on oral bradykinin B2-receptor antagonists.
- The company's clinical-stage biopharmaceutical business is advancing new alternatives to injected therapies for hereditary angioedema.
- Pharvaris NV's IPO on 5 February 2021 provided capital for further development of its therapies.
Weaknesses
- Pharvaris NV has only 65 full-time employees, which may limit operational capacity.
- The company is a clinical-stage biopharmaceutical firm with no commercialized products yet.
- Pharvaris NV's focus on hereditary angioedema may restrict market reach compared to broader therapies.
Opportunities
- The growing market for hereditary angioedema treatments offers significant expansion potential.
- Advancing oral therapies could replace current injected treatments, increasing market share.
- Pharvaris NV can leverage its IPO capital to expand clinical trials and product development.
Threats
- Competition from established pharmaceutical companies in the hereditary angioedema market.
- Regulatory hurdles may delay approval of new therapies for hereditary angioedema.
- Market acceptance of oral therapies over traditional injected treatments remains uncertain.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.